1 Executive Summary
2 Global Injectable Drugs Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3 Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4 Average Pricing Analysis
5 Macro-Economic Indicators
6 Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7 Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8 Recent Development, Policies & Regulatory Landscape
9 Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10 Global Injectable Drugs Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11 Global Injectable Drugs Market
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12 Global Injectable Drugs Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Product: Market Share (2020-2031F)
12.2.1. Freeze dried products, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Injectable sterile products, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3. By Packaging: Market Share (2020-2031F)
12.3.1. Ampules, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.2. Vials, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.3. Cartridges, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.4. Bottles, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4. By Device Type: Market Share (2020-2031F)
12.4.1. Conventional injectable, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.2. Prefilled syringes, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.3. Auto-injectors, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.4. Pen injectors, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.5. Variable injectors, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13 Company Profile
13.1. Becton, Dickinson and Company
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Baxter International Inc.
13.3. Sanofi
13.4. Pfizer Inc.
13.5. GlaxoSmithKline plc.
13.6. AstraZeneca
13.7. GILEAD SCIENCES, INC.
13.8. Merck & Co., Inc.
13.9. Novartis AG
13.10. Novo Nordisk A/S
13.11. Other Prominent Players
14 Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Select License Type
Our Clients
We have been working with some Fortune 500+ clients
.png){kind=icon}
